FY2024 Earnings Forecast for Sensus Healthcare, Inc. Issued By HC Wainwright (NASDAQ:SRTS)

Sensus Healthcare, Inc. (NASDAQ:SRTSFree Report) – HC Wainwright raised their FY2024 earnings estimates for shares of Sensus Healthcare in a report issued on Friday, February 9th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.08 per share for the year, up from their prior estimate of $0.04. HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.14 EPS.

Separately, TheStreet downgraded shares of Sensus Healthcare from a “c” rating to a “d+” rating in a research report on Friday, November 10th.

Get Our Latest Analysis on SRTS

Sensus Healthcare Trading Up 8.2 %

Shares of NASDAQ:SRTS opened at $4.20 on Monday. Sensus Healthcare has a 52 week low of $1.79 and a 52 week high of $7.60. The company’s 50 day moving average is $2.81 and its two-hundred day moving average is $2.72. The company has a market cap of $68.80 million, a PE ratio of 140.05 and a beta of 0.86.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SRTS. Advisor Group Holdings Inc. boosted its stake in Sensus Healthcare by 313.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 5,600 shares of the company’s stock worth $41,000 after purchasing an additional 4,244 shares during the period. Barclays PLC raised its position in Sensus Healthcare by 718.5% during the 4th quarter. Barclays PLC now owns 6,319 shares of the company’s stock worth $47,000 after buying an additional 5,547 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Sensus Healthcare during the 4th quarter worth $48,000. Rockefeller Capital Management L.P. raised its position in Sensus Healthcare by 75.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 7,000 shares of the company’s stock worth $51,000 after buying an additional 3,000 shares during the last quarter. Finally, BNP Paribas Arbitrage SNC purchased a new position in Sensus Healthcare during the 3rd quarter worth $94,000. Institutional investors and hedge funds own 20.56% of the company’s stock.

Sensus Healthcare Company Profile

(Get Free Report)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Further Reading

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.